slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 45,031-45,060
Pages 10,126
Rows per page 30
Component
45,031-45,060 of 303,780
03
Nuvalent | Investor Presentation Deck | 41 slidesNuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
04
The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
09
The slide uses a structured table to highlight gaps in current treatment standards.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
10
Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction2 hits
16
Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
24
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
36
The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
37
The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
38
The slide uses a 'Target Product Profile' framework to summarize the drug's key characteristics.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 2 hits
03
The slide uses a 2x2 grid layout to summarize key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
04
The slide uses a list of four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution2 hits
07
The slide features a split layout with a left-hand column for advisors/board and a right-hand grid for the leadership team, plus a footer highlighting 12 prior FDA approvals.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution2 hits
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution2 hits
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction2 hits
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
37
Uses a side-by-side comparison framework to contrast 2L+ (salvage) and 1L (front-line) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
39
The slide uses a 'ribbon' style callout box on the right for key product attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 2 hits
02
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations 2 hits
04
The slide uses a visual layout to associate each executive with specific past pharmaceutical successes.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
07
Includes a biological pathway diagram and a dose-response curve showing target validation.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
09
Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
10
Includes a patient-derived xenograft (PDX) study methodology diagram and a line chart showing tumor volume over time.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction2 hits
17
The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Voice Of Customer2 hits